Shares of Haemonetics (HAE) have gained 16.6% over the past four weeks to close the last trading session at $87.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $109.78 indicates a potential upside of 25.6%.The average comprises nine short-term price targets ranging from a low of $85 to a high of $125, with a standard deviation of $12.49. While the lowest estimate indicates a ...